FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 494,300 shares, a drop of 5.1% from the April 30th total of 520,800 shares. Based on an average daily trading volume, of 133,400 shares, the days-to-cover ratio […]
FSD Pharma Inc (CNSX:HUGE – Get Rating) Director Zeeshan Saeed bought 23,000 shares of the company’s stock in a transaction on Thursday, April 13th. The stock was bought at an average cost of $2.52 per share, for a total transaction of $57,960.00. FSD Pharma Price Performance About FSD Pharma (Get Rating) FSD Pharma Inc operates […]
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a.
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9.
FSD Pharma Inc incorporates new subsidiary to capitalize on drug development incentives in Australia proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.